| 1. |
Sasada T, Noguchi M, Yamada A, Itoh K. Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother. 2012 Sep 1;8(9). [Epub ahead of print] |
| 2. |
Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. International Journal of Oncology40: 1492-1500, 2012. |
| 3. |
Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer (in press) |
| 4. |
Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Akira Yamada A, Itoh K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 71:470-479, 2011. |
| 5. |
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Experimental and therapeutic medicine 2:109-117, 2011. |
| 6. |
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int 108:831-838, 2011. |
| 7. |
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh Uhi, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biology & Therapy 12:1266-79, 2011 |
| 8. |
Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470-9, 2011. |
| 9. |
Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K and Yamada A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncology Reports 25: 57-62, 2011 |
| 10. |
Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K, Shichijo S. A β-tubulin 5-derived peptide induces cytotoxic T lymphocytes restricted to the HLA-A24 allele in prostate cancer patients. Experimental and Therapeutic Medicine 1: 833-839, 2010. |
| 11. |
Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Science 101:2010-2014, 2010. |
| 12. |
Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, A-Hon Kwon, Komatsu N, Itoh K, Noguchi M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Rep 24: 795-801, 2010. |
| 13. |
Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccine. EJC 46: 1514-1519, 2010. |
| 14. |
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59: 1001-1009, 2010. |
